Theolytics Doses First Patient in Phase I/IIa Trial of THEO-260 in Ovarian Cancer
THEO-260 is a mechanistically novel oncolytic immunotherapy developed to tackle the stromal rich tumour microenvironment (TME) evident in ...
Novel CAR T-cell therapy demonstrates efficacy and safety in preclinical models of HER2-positive solid tumors
One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...
Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation
Janux Therapeutics' innovative cancer treatment shows promise in reducing side effects and improving patient outcomes, but stock risks remain. See more on JANX.
經濟通ET Net4h
Short Selling Turnover (Main Board) up to morning close(1)
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such ...